---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-164011"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2023-06-09T23:59:59+00:00"
generated_at: "2026-06-14T04:03:26.005291+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma shareholders elect directors, approve say-on-pay, and ratify auditor

## Summary
- Re-elected Class III directors Richard Heyman (28.7M for), David Mack (35.2M for), and Laurie Stelzer (34.1M for).
- Non-binding advisory vote on executive compensation approved with 34.5M for, 0.8M against.
- Ratified Ernst & Young as independent auditor for FY2023 with 39.9M for, 2,087 against.
- All proposals passed; annual meeting held virtually on June 8, 2023.

## SEC filing metadata
- accession: 0001193125-23-164011
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2023-06-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000119312523164011/0001193125-23-164011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000119312523164011/d479825d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-164011
- JSON: https://secwatch.observer/filing/0001193125-23-164011.json
- Plain text: https://secwatch.observer/filing/0001193125-23-164011.txt

## Key facts
- Shareholder Votes
  PMV Pharmaceuticals, Inc. shareholders approved Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers at the 2023-06-08 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-08
  source text: Proposal 2. Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers The Company’s stockholders approved, on a non-binding advisory basis, the compensation paid to its named executive officers as described in the Company’s definitive proxy statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 28, 2023 (the “Proxy Statement”). The final voting results are as follows: FOR AGAINST ABSTAIN BROKER NON-VOTE 34,537,890 836,543 1,065 4,491,578
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699382/000119312523164011/0001193125-23-164011-index.htm
- Shareholder Votes
  PMV Pharmaceuticals, Inc. shareholders approved Election of Directors at the 2023-06-08 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-08
  source text: Proposal 1. Election of Directors The Company’s stockholders elected the three persons listed below as Class III Directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors has been duly elected and qualified, or until the earlier of the respective director’s death, resignation or removal. The final voting results are as follows: FOR WITHHELD BROKER NON-VOTE Richard Heyman, Ph.D. 28,709,696 6,665,802 4,491,578 David H. Mack, Ph.D. 35,181,696 193,802 4,491,578 Laurie Stelzer 34,128,780 1,246,718 4,491,578
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699382/000119312523164011/0001193125-23-164011-index.htm
- Shareholder Votes
  PMV Pharmaceuticals, Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2023-06-08 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-08
  source text: Proposal 3. Ratification of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The final voting results are as follows: FOR AGAINST ABSTAIN 39,864,451 2,087 538
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699382/000119312523164011/0001193125-23-164011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.